C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker

References

• World Health Organization. Stroke 1989. Recommendations on stroke prevention, diagnosis and therapy. Report of the WHO Task Force on stroke and other cerebrovascular disorders. Stroke 20, 1407–1431 (1989).
   Google Scholar
• Sarti C, Rastenyte D, Cepaitis Z et al International trends in mortality from stroke, 1968 to 1994. Stroke 31, 1588–1601 (2000).
   PubMed Web of Science ®Google Scholar
• Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat. Q. 41, 155–168 (1988).
   Google Scholar
• Howard G, Howard VJ, Katholi C et al. Decline in US stroke mortality: an analysis of temporal patterns by sex, race and geographic regions. Stroke 32, 2213–2210 (2001).
   PubMed Web of Science ®Google Scholar
• Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J18, 1231–1248 (1997).
   Google Scholar
• KLag MJ, Whelton PK, Seidler AJ. Decline in US stroke mortality: demographic trends and antihypertensive treatment. Shoke20, 14–21 (1989).
   Google Scholar
• American Heart Association. Stroke. In: Heart Disease and Stoke Statistics —2003 Update. American Heart Association, TX, USA (2003).
   Google Scholar
• Rodriguez BL, D'Agostino R, Abbott RD et al Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke 33, 236–237 (2002).
   PubMed Web of Science ®Google Scholar
• •Interesting paper that shows Japanese—American men now have a lower stroke risk than Caucasians.
   Google Scholar
• Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JA/V/A 288, 1388–1395 (2002).
   Google Scholar
• •Excellent review of risk factors for stroke and relative efficacy of treatment.
   Google Scholar
• World Population Ageing: 1950–2050. United Nations, 2002. Department of Economic and Social Affairs Population Division. United Nations Publication Sales No. E.02.XIII.3.
   Google Scholar
• Fassbender K, Bertsch T, Mielke 0 et al Adhesion molecules in cerebrovascular diseases: evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke 30,1647–1650 (1999).
   PubMed Web of Science ®Google Scholar
• Stary HC, Chandler AB, Glagov S et al A definition of initial, fatty streak and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89,2462–2478 (1994).
   PubMed Web of Science ®Google Scholar
• Napoli C, D'Armiento FP, Mancini FP et al Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. j Clin. Invest. 100, 2680–2690 (1997).
   PubMed Web of Science ®Google Scholar
• Newman AB, Arnold AM, Naydeck BL et al Cardiovascular Health Study Research Group. 'Successful aging': effect of subclinical cardiovascular disease. Arch. Intern. Med. 163, 2315–2322 (2003).
   Google Scholar
• •Interesting paper that links C-reactive protein (CRP) to subclinical cardiovascular disease (CVD) and looks at its impact on disability in older age.
   Google Scholar
• Bernstein AM, Willcox BJ, Tamaki H et al. Autopsy of an Okinawan—Japanese centenarian: absence of many age-related diseases. j Cerontol Med. Sci (2004) (In Press).
   Google Scholar
• •Interesting paper that shows the remarkable age range at which CVD can develop in humans and the potential resistance to CVD in centenarians.
   Google Scholar
• Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular risk prediction. j Intern. Med. 252,283–294 (2002).
   PubMed Web of Science ®Google Scholar
• Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke 34,2518–2532 (2003).
   PubMed Web of Science ®Google Scholar
• •Excellent current review of this topic including the role of CRP in CVD.
   Google Scholar
• Rohde LE, Hennekens CH, Ridker PM. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler. Thromb. Vasc. Biol. 19,1595-1599 (1999).
   Google Scholar
• Hackman A, Abe Y, Insull W Jr et al. Levels of soluble adhesion molecules in patients with dyslipidemia. Circulation 93, 1334–1338 (1996).
   Google Scholar
• Ferri C, Desideri G, Valenti M et al. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension 34,568–573 (1999).
   PubMed Web of Science ®Google Scholar
• Grayson JT. Background and current knowledge of Chlamyclia pneumoniae and atherosclerosis. j Infect. Dis. 181, S402—S410 (2000).
   Web of Science ®Google Scholar
• Yamashita K, Ouchi K, Shirai M et al Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 29,773–778 (1998).
   PubMed Web of Science ®Google Scholar
• Virok D, Ki values Z, Karai L et al Chlamydia pneumoniae in atherosclerotic middle cerebral artery. Stroke 32, 1973–1976 (2001).
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, Anderson JL. Infectious serology and atherosclerosis: how burdensome is the risk? Circulation 107, 220–222 (2003).
   PubMed Web of Science ®Google Scholar
• Tohgi H, Konno S, Takahashi S et al. Activated coagulationifibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thrombosis Res 100, 373–379 (2000).
   PubMed Web of Science ®Google Scholar
• Walsh PN, Schmaier AH. Platelet- coagulant protein interactions. In: I-Lemostasis, and Thrombosis: Basic Principles and Clinical Practice. Colman RVV, Hirsh J, Marder VS. (Eds). JB Lippincott, PA, USA 689–709 (1987).
   Google Scholar
• Booth NA, Simpson AJ, Croll A et al Plasminogen activator inhibitor in plasma and platelets. BE j I-Lematol 70,327–333 (1988).
   Google Scholar
• Lagrand WK, Visser CA, Hermens WT et al. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 100, 96–102 (1999).
   PubMed Web of Science ®Google Scholar
• Warlow C, Sudlow C, Dennis M et al. Stroke. Lancet 362,1211–1224 (2003).
   PubMed Web of Science ®Google Scholar
• Harbison J, Hossain 0, Jenkinson D et al Diagnostic accuracy of stroke referrals from primary care, emergency room physicians and ambulance staff using the face arm speech test. Stroke 34,71–76 (2003).
   PubMed Web of Science ®Google Scholar
• Von Kummer R, Bourguain H, Bastianello S et al, for the European Co-operative Acute Stroke Study II Group. Early prediction of irreversible brain damage after ischemic stroke at CT Radiology 219, 95–100 (2001).
   Google Scholar
• Lyden P. Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator. Stroke 34,821–822 (2003).
   PubMed Web of Science ®Google Scholar
• Tomsick TA. Tick tock, doc: the rapid evaluation of acute stroke to direct therapy and improve patient outcome. AJNR21, 1177–1179 (2000).
   PubMed Web of Science ®Google Scholar
• Atlas SW, Thulborn KR. MR detection of hyperacute parenchymal hemorrhage of the brain. AJNR19, 1471–1477 (1998).
   PubMed Web of Science ®Google Scholar
• Soong JC, Bradley WG, Chen DY et al FLAIR should be more sensitive than CT for the detection of acute subarachnoid hemorrhage. Radiology209,471 (1998).
   PubMedGoogle Scholar
• Marler JR, Tilley BC, Lu M et al Early stroke treatment associated with better outcome: the NINDS rtPA stroke study. Neurology55, 1649–1655 (2000).
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl. I Med. 333, 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• Connors JJ III. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. Rev Canliovasc. Med. 3\(Suppl. 2), S92—S99 (2002).
   Google Scholar
• Chen ZM, Sandercook P, Pan HC et al Indication for early aspirin use in acute ischemic stroke: a combined analysis of 40000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31, 1240–1249 (2000).
   PubMed Web of Science ®Google Scholar
• Kerber CW, Barr JD, Berger RM, Chopko BW Snare retrieval of intracranial thrombus in patients with acute stroke. Vasc. Interv Radio. 13,1269–1274 (2002).
   PubMed Web of Science ®Google Scholar
• •A new and exciting area of potential therapy for acute stroke.
   Google Scholar
• Gorelick PB, Sacco RL, Smith DB et al Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAIVIA 281,1112–1120 (1999).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Gasowski J, Wang JG et al Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355, 865–872 (2000).
   PubMed Web of Science ®Google Scholar
• Schatz IJ, Masaki K, Yano K et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 358, 351–355 (2001).
   PubMed Web of Science ®Google Scholar
• Benfante R, Yano K, Hwang LJ et al Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk. Stmke 25,814–820 (1994).
   Google Scholar
• Hankey JG, Warlow CR Treatment and secondary prevention of stroke: evidence, costs and effects on individuals and populations. Lancet 354,1457–1463 (1999).
   PubMed Web of Science ®Google Scholar
• Gueyffier F, Bulpitt C, Boissel JP et al, for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. Lancet353, 793–796 (1999).
   PubMed Web of Science ®Google Scholar
• Arenillas JF, Alvarez-Sabin J, Molina CA et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stmke 34,2463–2470 (2003).
   Google Scholar
• Rost NS, Wolf PA, Kase CS et al Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham Study. Stmke 32, 2575–2579 (2001).
   Google Scholar
• Curb JD, Abbott RD, Rodriguez BL et al C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 207,2016–2020 (2003).
   Google Scholar
• •The first and one of the few papers on CRP in a minority population (Asian—Americans). Demonstrates roughly equivalent risk of high CRP for stroke as for Caucasians.
   Google Scholar
• Cao JJ, Thach C, Manolio TA etal. C- reactive protein, carotid intimal-media thickness and incidence of ischemic stroke in the elderly: The Cardiovascular Health Study. Circulation 108,166–170 (2003).
   PubMed Web of Science ®Google Scholar
• •One of the few papers on CRP and stroke in the elderly.
   Google Scholar
• Curb JD, Abbott RD, MacLean CJ et al. Age-related changes in stroke risk in men with hypertension and normal blood pressure. Stroke 27,819–824 (1996).
   PubMed Web of Science ®Google Scholar
• ••Excellent paper on the controversial topicof blood pressure and stroke risk in the elderly.
   Google Scholar
• Cesari M, Penninx BWJH, Newman AB et al Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition Study). Am. J. Cardiol 92, 522–528 (2003).
   PubMed Web of Science ®Google Scholar
• van Exel E, Gussekloo J, de Craen AJM et al Inflammation and stroke. The Leiden 85-Plus Study. Stroke 33, 1135–1138 (2002).
   Google Scholar
• Koenig W C-reactive protein and cardiovascular risk: has the time come for screening the general population? Clin. Chem. 47, 9–10 (2001).
   Web of Science ®Google Scholar
• Morrow DA, Ridker PM. High sensitivity C-reactive protein (hs-CRP): a novel risk marker in cardiovascular disease. Prey Cardiol 1, 13–16 (1999).
   Google Scholar
• Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103, 1813–1818 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C- reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363–369 (2003).
   PubMed Web of Science ®Google Scholar
• Ridker PM. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 108, E81—E85 (2003).
   Google Scholar
• •Concise and readable summary of the case for CRP screening in CVD.
   Google Scholar
• Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin. Chem. 47, 28–30 (2001).
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systematic responses to inflammation. N Engl. J. Med. 340, 448–454 (1999).
   PubMed Web of Science ®Google Scholar
• Du Clos TVV. Function of C-reactive protein. Ann. Med. 32, 274–278 (2000).
   PubMed Web of Science ®Google Scholar
• Sakkinen P, Abbott RD, Curb JD et al. C- reactive protein and myocardial infarction. Clin. Epidemiol 55, 445–451 (2002).
   PubMed Web of Science ®Google Scholar
• •The first and one of the few papers on CRP and myocardial infarction (MI) in a minority population (Asian—Americans). Demonstrates roughly equivalent risk of high CRP for Mt compared with Caucasians.
   Google Scholar
• Ridker PM, Cushman M, Stampfer MJ et al Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl. J. Med 336, 973–979 (1997).
   PubMed Web of Science ®Google Scholar
• •Classic early paper on CRP and CVD. Also shows CRP is lower in regular users of aspirin.
   Google Scholar
• Ridker PM, Cushman M, Stampfer MJ et al Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97, 425–428 (1998).
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy RP, Shaten J et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J. Epidemiol 144, 537–547 (1996).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE et al C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl. J. Med 342, 836–843 (2000).
   PubMed Web of Science ®Google Scholar
• •High impact paper showing that CRP was more predictive than cholesterol screening for CVD in women.
   Google Scholar
• Tracy RP, Lemaitre RN, Psaty BM et al Relationship of C-reactive protein to the risk of cardiovascular disease in the elderly. Arterioscler. Thromb. Vasc. Biol. 17, 1121–1127 (1997).
   PubMed Web of Science ®Google Scholar
• •One of the few studies of CRP and CVD in the elderly.
   Google Scholar
• Cesari M, Penninx BW, Newman AB et al Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108, 2317–2322 (2003).
   PubMed Web of Science ®Google Scholar
• •One of the few studies of CRP and CVD in the elderly. Suggests that interleuldn-6 may be a better marker than CRP for stroke risk in the elderly.
   Google Scholar
• Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Cirr. Res. 89, 763–771 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285, 2481–2485 (2001).
   PubMed Web of Science ®Google Scholar
• ••Excellent comparison of the relativepredictive abilities of different novel risk factors for atherosclerosis suggesting that CRP is more predictive than other novel risk factors and a better screening tool.
   Google Scholar
• Ridker PM, Glynn RJ, Hennekens CH. C- reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97, 2007–2011 (1998).
   Google Scholar
• Di Napoli M, Papa E Clinical use of C- reactive protein for prognostic stratification in ischemic stroke: has the time come for including it in the patient risk profile? Stroke 34, 375 (2003).
   PubMed Web of Science ®Google Scholar
• Tchernof A, Noran A, Sites CK et al Weight loss reduced C-reactive protein levels in obese postmenopausal women. Circulation 105, 564–569 (2002).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RVV et al Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499–511 (2003).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive evidence-based summarystatement and guidelines for health professionals regarding CRP testing.
   Google Scholar
• Ridker PM, Buring JE, Shih J et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98, 731–733 (1998).
   PubMed Web of Science ®Google Scholar
• Ridker PM. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur Hear tI 22, 2135–2137 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer M et al Long- term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100, 230–235 (1999).
   PubMed Web of Science ®Google Scholar
• •Good paper showing statins can be effective in lowering CRP and thus may play a role in reducing inflammation.
   Google Scholar
• Chew D, Bhatt DL, Robbins MA et al. Effect of dopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am. Carcliol 88, 672–674 (2001).
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kereiakes DJ, Mascelli MA et al Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation l04, 163–167 (2001).
   Google Scholar
• Haffner SM, Greenberg AS, Weston WM et al Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 106, 679–684 (2002).
   PubMed Web of Science ®Google Scholar
• •Interesting paper showing that the glitazones may also play a role in reducing inflammation and that CRP may be linked to glycemic control.
   Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl. J. Med 342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin. Chem. 45, 2136–2141 (1999).
   Google Scholar
• Roberts WL, Sedrick R, Moulton L et al Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Gun. Chem. 46461–468 (2000).
   Google Scholar
• Ridker PM, Rifai N, Rose L etal. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl. J. Med. 347,1557–1565 (2002).
   Google Scholar
• •Good paper making the case that CRP may be more predictive than cholesterol for CVD.
   Google Scholar
• Albert MA, Danielson E, Rifai N et al Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation CRP Evaluation (PRINCE). JAIVIA 286, 64–70 (2001).
   PubMed Web of Science ®Google Scholar
• Plenge JK, Hernandez TL, Weil KM et al Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106,1447–1452 (2002).
   PubMed Web of Science ®Google Scholar
• Jenkins DJ, Kendall CW, Marchie A et al Effects of a dietary portfolio of cholesterol-lowering foods vs. lovastatin on serum lipids and C-reactive protein. 161/11A 290, 502–510 (2003).
   Google Scholar
• •Excellent paper showing the powerful effects of specific dietary compounds in lowering lipids and CRP equivalent in efficacy to first generation statins.
   Google Scholar
• Tomaszewski M, Charchar FJ, Przybycin M et al. Strikingly low circulating CRP concentrations in ultramarathon runners independent of markers of adiposity: how low can you go? Arterioscler. Thromb. Vasc. Biol. 23,1640–1644 (2003).
   PubMed Web of Science ®Google Scholar
• •Provocative paper showing that exercise may lower CRP levels independent of body fat loss.
   Google Scholar
• Alberts MJ. Stroke genetics update. Stroke 34,342–344 (2003).
   PubMed Web of Science ®Google Scholar
• •Good current and concise review of this topic.
   Google Scholar
• Tournier-Lasserve E. New players in the genetics of stroke. N Engl. J. Merl 347, 1711–1712 (2002).
   PubMed Web of Science ®Google Scholar
• Brull DJ, Serrano N, Zito F et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 11, 2063–2069 (2003).
   Google Scholar
• •Important new information on how subtle variations in human genes might affect CVD risk through variation in CRP levels.
   Google Scholar
• Toyoda K, Chu Y, Heistad DD. Gene therapy for cerebral vascular disease: update 2003. Br. Pharmacol 139,1–9 (2003).
   Google Scholar